Health

EMD Serono to announce long-term data in numerous cancers at ESMO 2020

EMD Serono to announce long-term data in numerous cancers at ESMO 2020

Health

EMD Serono Inc., the biopharmaceutical business of Germany-based Merck KGaA in the United States and Canada, has reportedly announced that it will present over 30 abstracts related to the company’s clinical studies in oncology at ESMO (the European Society for Medical Oncology) Virtual Congress 2020, which will be held between Sept. 19 -21.

The abstracts span EMD’s oncology programs across numerous innovative mechanisms and modalities that have the potential to advance treatment across a range of tumor types including lung, biliary tract, and urothelial cancers.

Sources cite that EMD will present new outcomes from Phase III

Casma Therapeutics raises $50M in TCG led Series-B funding round

Casma Therapeutics raises $50M in TCG led Series-B funding round

Health

Casma Therapeutics, Inc., has reportedly raised an amount of $50 million in a Series-B funding initiative led by The Column Group. While Schroder Adveq and Eventide Asset Management, LLC, have participated in the financing round as new investors, Third Rock Ventures has been part of initiative as an existing investor.

The Column Group’s Millie Ray will reportedly join Casma’s Board of Directors and Eventide Asset Management LLC’s Chief Investment Officer, Finny Kuruvilla, will become a board observer, as stated in the round.

According to Keith Dionne, the Chief Executive Officer at Casma Therapeutics, the company is th

OncoImmune secures $56M in HM Capital co-led Series-B funding round

OncoImmune secures $56M in HM Capital co-led Series-B funding round

Health

OncoImmune Inc., has reportedly announced that it has successfully raised a sum of $56 million in a Series B funding initiative co-led by a blue-chip investor and HM Capital. Other participants of the funding round comprise the company’s existing investors, including Kaitai Capital and 3E Bioventures Capital, along with new investors, comprising GF Xinde and GBA Fund. OncoImmune has planned to utilize the financing for the expansion of its product pipeline and supporting its novel therapeutic initiatives in late stage clinical trials.

According to Yang Liu, the CEO and Chairman at OncoImmune, the company is thankful to its investors for their continued support and co

Kitov discloses the first dosing in NT219’s Phase 1/2 clinical trial

Kitov discloses the first dosing in NT219’s Phase 1/2 clinical trial

Health

Kitov Pharma Limited has reportedly announced its dosing of the first patient in the Phase 1/2 clinical trial of NT219. The candidate is a novel small molecule targeting STAT3 and IRS1/2, major drug resistance pathways and important oncogenic drivers in numerous hard-to-treat cancers.

As per sources, the Phase 1/2 trial focuses on the evaluation of NT219 as monotherapy for the treatment of advanced solid tumors. The trial also intends to test the integration of NT219 with an EGFR called cetuximab, which is responsible for blocking monoclonal antibody, in the treatment of metastatic and/or recurrent solid tumors and colorectal adenocarcinoma or head and neck cancer.

Eisai will now look after Equfina’s marketing & manufacturing approval

Eisai will now look after Equfina’s marketing & manufacturing approval

Health

Eisai Co. Ltd., the Japan-based pharmaceutical firm, has reportedly announced that it will acquire manufacturing and marketing rights of ‘Equfina 50mg’ tablets in Japan from Meiji Seika Pharma Co. Ltd.

Developed for Parkinson's disease treatment, Meiji conducted clinical trials of the drug and obtained its marketing and manufacturing approval in September 2019. Since then, Eisai has sold Equfina in Japan as a distributor.  

As per the license agreement inked between Meiji and Eisai, Eisai will take over the manufacturing and marketing approval of the drug from September 23, 2020. Eisai, a distributor, and manuf

Prime Healthcare completes acquisition of St. Francis Medical Center

Prime Healthcare completes acquisition of St. Francis Medical Center

Health

Prime Healthcare Services, the U.S-based private healthcare company, today highlighted its continued efforts to preserve the healthcare mission and legacy of St. Francis Medical Center. The company has reportedly announced that it has acquired St. Francis Medical Center after getting approval from U.S. Bankruptcy Court for the Central District of California.

 

Sources cite that Prime has acquired St. Francis for a net consideration of more than USD 350 million including over USD 250 million cash. The company will also invest $47 million in St. Francis to finance capital improvements, including significant system upgrades and technology investments. It is also agreed to make offers of employment to substantially all St.

Dr. Reddy’s introduces generic version of Ciprodex in US Market

Dr. Reddy’s introduces generic version of Ciprodex in US Market

Health

Hyderabad-based Dr. Reddy’s Laboratories Limited has reportedly launched a generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension in the U. S market, after getting approval from the US FDA (Food and Drug Administration).

Ciprodex is generally recommended for the treatment of infections developed by susceptible isolates of established microorganisms under the specific conditions of AOM (Acute Otitis Media) in pediatric and AOE( Acute Otitis Externa) in adult, pediatric, and elderly patients.

Marc Kikuchi, who is the CEO of North America Generics business at Dr. Reddy’s Laboratories seemed to be rather satisfied with the first-to-market product launch and has appreciated the firm

Genentech announces updated Phase III clinical data of Etrolizumab

Genentech announces updated Phase III clinical data of Etrolizumab

Health

Genentech, a biotechnology corporation that operates as an independent unit within Roche Group, has reportedly announced the top-line results from its Phase III clinical trial of etrolizumab in patients with moderately to severely active ulcerative colitis.

Sources cite that studies assessing etrolizumab as an induction therapy demonstrated mixed results. HIBISCUS I induction clinical study in people without prior anti-TNF (Anti-tumor Necrosis Factor) treatment apparently met the primary endpoint.

On the other hand, the HIBISCUS II induction clinical study, which comprised patients without previous anti-TNF treatment, didn’t achieve its primary endpoint.

Studies assessing etrolizumab as a maintenance therapy

WITHmyDOC launches RPM@Home™ kit to aid Healthcare Professionals

WITHmyDOC launches [email protected]™ kit to aid Healthcare Professionals

Health
"

Florida-based healthcare technology company WITHmyDOC has reportedly introduced [email protected]™, a remote patient monitoring (RPM) kit. It is being speculated that the kit may revolutionize the healthcare sector.

Sources cite that [email protected]™ transmits real-time biometric data of patients to healthcare providers using a web-based intelligence platform. [email protected] provides real-time data and facilitates proactive intervention by assisting chronic care management and telehealth visits.

With the help of WITHmyDOC’s RPM platform, healthcare providers will be able to review the patient’s biometric data as regularly as required during office visits. Hence it will make it easier to spot, diagno